This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petraitis, V.
Right arrow Articles by Walsh, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petraitis, V.
Right arrow Articles by Walsh, T. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 1998, p. 2898-2905, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

Vidmantas Petraitis,1 Ruta Petraitiene,1 Andreas H. Groll,1 Aaron Bell,1 Diana P. Callender,1 Tin Sein,1 Robert L. Schaufele,1 Carl L. McMillian,2 John Bacher,3 and Thomas J. Walsh1,*

Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1 and Surgery Branch, Veterinary Resources Services, National Center for Research Resources,3 National Institutes of Health, Bethesda, Maryland, and Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana2

Received 24 February 1998/Returned for modification 19 May 1998/Accepted 9 August 1998

LY303366 is a novel semisynthetic derivative of echinocandin B and a potent inhibitor of fungal (1,3)-beta -D-glucan synthase. The antifungal efficacy and safety of LY303366 were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Treatment study groups were either not treated (controls) or treated with amphotericin B (AmB) at 1 mg/kg of body weight per day or with LY303366 at 1, 5, 10, and 20 mg/kg/day. In rabbits treated with LY303366, there was a significant improvement in survival and a reduction in organism-mediated pulmonary injury measured by the number of infarcts, total lung weight, and ultrafast computerized tomography scan pulmonary lesion score. Rabbits receiving prophylactic LY303366 also demonstrated significant improvement in survival and reduction in organism-mediated pulmonary injury. AmB and LY303366 had comparable therapeutic efficacies by all parameters with the exception of reduction in tissue burden of A. fumigatus, where AmB was superior to LY303366. LY303366 demonstrated a dose-dependent effect on hyphal injury with progressive truncation, swelling, and vacuolization. LY303366 administered in single doses of 1, 5, 10, and 20 mg/kg demonstrated dose-proportional increases in the maximum concentration of drug in plasma and the area under the concentration-time curve from 0 to 72 h with no changes in plasma drug clearance. The 1-mg/kg dosage maintained plasma drug levels above the MIC for 18 h, and dosages of >= 5 mg/kg maintained plasma drug levels above the MIC for the entire 24-h dosing interval. There was no significant elevation of the concentrations of hepatic transaminases or creatinine in serum in LY303366-treated rabbits. In summary, LY303366 improved survival and decreased pulmonary injury with no apparent toxicity in the treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits.

* Corresponding author. Mailing address: Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Rm. 13N240, 10 Center Dr., Bethesda, MD 20892. Phone: (301) 402-0023. Fax: (301) 402-0575. E-mail: walsht{at}pbmac.nci.nih.gov.

Antimicrobial Agents and Chemotherapy, November 1998, p. 2898-2905, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M. E., Scalise, G., Barchiesi, F. (2009). Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 4035-4039 [Abstract] [Full Text]  
  • Lewis, R. E., Albert, N. D., Kontoyiannis, D. P. (2008). Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 52: 4178-4180 [Abstract] [Full Text]  
  • Lewis, R. E., Albert, N. D., Kontoyiannis, D. P. (2008). Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61: 1140-1144 [Abstract] [Full Text]  
  • van de Sande, W. W. J., van Vianen, W., ten Kate, M. T., Vissers, J., Laurijsens, J., Tavakol, M., Rijnders, B. J. A., Mathot, R. A. A., Bakker-Woudenberg, I. A. J. M. (2008). Caspofungin Prolongs Survival of Transiently Neutropenic Rats with Advanced-Stage Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 52: 1345-1350 [Abstract] [Full Text]  
  • Dennis, C. G., Greco, W. R., Brun, Y., Youn, R., Slocum, H. K., Bernacki, R. J., Lewis, R., Wiederhold, N., Holland, S. M., Petraitiene, R., Walsh, T. J., Segal, B. H. (2006). Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47phox-/- Mouse Model of Chronic Granulomatous Disease. Antimicrob. Agents Chemother. 50: 422-427 [Abstract] [Full Text]  
  • Benjamin, D. K. Jr., Driscoll, T., Seibel, N. L., Gonzalez, C. E., Roden, M. M., Kilaru, R., Clark, K., Dowell, J. A., Schranz, J., Walsh, T. J. (2006). Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections. Antimicrob. Agents Chemother. 50: 632-638 [Abstract] [Full Text]  
  • Philip, A., Odabasi, Z., Rodriguez, J., Paetznick, V. L., Chen, E., Rex, J. H., Ostrosky-Zeichner, L. (2005). In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp.. Antimicrob. Agents Chemother. 49: 3572-3574 [Abstract] [Full Text]  
  • Graybill, J. R., Hernandez, S., Bocanegra, R., Najvar, L. K. (2004). Antifungal Therapy of Murine Aspergillus terreus Infection. Antimicrob. Agents Chemother. 48: 3715-3719 [Abstract] [Full Text]  
  • Odabasi, Z., Paetznick, V. L., Rodriguez, J. R., Chen, E., Ostrosky-Zeichner, L. (2004). In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates. Antimicrob. Agents Chemother. 48: 1912-1915 [Abstract] [Full Text]  
  • Graybill, J. R., Bocanegra, R., Gonzalez, G. M., Najvar, L. K. (2003). Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 52: 656-662 [Abstract] [Full Text]  
  • Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2002). The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro. Antimicrob. Agents Chemother. 46: 3001-3012 [Abstract] [Full Text]  
  • Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2001). Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate. Antimicrob. Agents Chemother. 45: 3474-3481 [Abstract] [Full Text]  
  • Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., Heitman, J. (2001). Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR. Antimicrob. Agents Chemother. 45: 3162-3170 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitiene, R., Petraitis, V., Lyman, C. A., Bacher, J. S., Piscitelli, S. C., Walsh, T. J. (2001). Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling. Antimicrob. Agents Chemother. 45: 2845-2855 [Abstract] [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Sein, T., Schaufele, R. L., Lyman, C. A., Francesconi, A., Bacher, J., Piscitelli, S. C., Walsh, T. J. (2001). Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. Antimicrob. Agents Chemother. 45: 471-479 [Abstract] [Full Text]  
  • Groll, A. H., Gullick, B. M., Petraitiene, R., Petraitis, V., Candelario, M., Piscitelli, S. C., Walsh, T. J. (2001). Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits. Antimicrob. Agents Chemother. 45: 596-600 [Abstract] [Full Text]  
  • Reichenberger, F., Habicht, J.M., Gratwohl, A., Tamm, M. (2001). Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19: 743-755 [Abstract] [Full Text]  
  • Roberts, J., Schock, K., Marino, S., Andriole, V. T. (2000). Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 44: 3381-3388 [Abstract] [Full Text]  
  • Balani, S. K., Xu, X., Arison, B. H., Silva, M. V., Gries, A., DeLuna, F. A., Cui, D., Kari, P. H., Ly, T., Hop, C. E. C. A., Singh, R., Wallace, M. A., Dean, D. C., Lin, J. H., Pearson, P. G., Baillie, T. A. (2000). Metabolites of Caspofungin Acetate, a Potent Antifungal Agent, in Human Plasma and Urine. Drug Metab. Dispos. 28: 1274-1278 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., Kuwahara, S. (2000). Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis. Antimicrob. Agents Chemother. 44: 614-618 [Abstract] [Full Text]  
  • Matsumoto, S., Wakai, Y., Nakai, T., Hatano, K., Ushitani, T., Ikeda, F., Tawara, S., Goto, T., Matsumoto, F., Kuwahara, S. (2000). Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 44: 619-621 [Abstract] [Full Text]  
  • Clemons, K. V., Sobel, R. A., Stevens, D. A. (2000). Toxicity of LY303366, an Echinocandin Antifungal, in Mice Pretreated with Glucocorticoids. Antimicrob. Agents Chemother. 44: 378-381 [Abstract] [Full Text]  
  • Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., Kuwahara, S. (2000). In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi. Antimicrob. Agents Chemother. 44: 57-62 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»